🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,562 results for “Cancer” Clear

  1. Paclitaxel

    CNS Pharmaceuticals

    Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  2. Paclitaxel

    United Therapeutics Europe Ltd

    Clinical Stage III Gastric Cancer AJCC v8

    phase 2 small molecule active

    1 trial

  3. Paclitaxel Kabi 6 mg/ml koncentrátum oldatos infúzióhoz, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CARBOPLATINE MEDAC 10 mg/mL, solution à diluer pour perfusion, 68Ga-FAPI-46, DOXORUBICINE ARROW 2 mg/ml, solution pour perfusion, Epirubicin Eugia 2 mg/ml oplossing voor injectie, Cyclophosphamid beta 500 mg/ml Konzentrat zur Herstellung einer Injektions-/Infusionslösung

    The George Institute

    Breast cancer

    phase 2 small molecule active

    1 trial

  4. Paclitaxel and TAK-228

    Takeda

    Metastatic Urothelial Cancer

    phase 2 other active

    1 trial

  5. Palbociclib 125Mg Tab

    United Therapeutics Europe Ltd

    ER+ Breast Cancer

    phase 2 small molecule active

    1 trial

  6. Pamorelin® LA 3,75 mg Pulver und Lösungsmittel zur Herstellung einer Depot-Injektionssuspension, RO7197597, ANASTROZOLE ACCORD 1 mg, comprimé pelliculé

    Partner Therapeutics Limited

    ER-positive/HER2-negative early breast cancer

    phase 2 small molecule active

    1 trial

  7. Pancreatoduodenectomy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pancreatic Cancer

    phase 2 other active

    1 trial

  8. Panitumumab

    BRIGHT MINDS BIOSCIENCES INC.

    Advanced Head and Neck Squamous Cancer

    phase 2 small molecule completed

    1 trial

  9. Panitumumab + TAS-102

    Takeda

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  10. Panzem Nanocrystal Colloidal Dispersion (NCD)

    CASI Pharmaceuticals

    Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  11. Panzem® NCD

    CASI Pharmaceuticals

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

  12. Patritumab deruxtecan

    Daiichi Sankyo

    Metastatic or Locally Advanced EGFR mutated Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  13. Paxalisib

    KAZIA THERAPEUTICS LTD

    Childhood Cancer

    phase 2 small molecule active

    1 trial

  14. Pegylated Irinotecan

    Nektar Therapeutics UK Limited

    Stage IV Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule completed

    1 trial

  15. Pelareorep

    ONCOLYTICS BIOTECH INC

    Anatomic Stage IV Breast Cancer AJCC v8

    phase 2 mab active

    1 trial

  16. Pelareorep

    ONCOLYTICS BIOTECH INC

    Anal Cancer Metastatic

    phase 2 small molecule active

    1 trial

  17. Pemazyre 4.5 mg tablets

    Ningbo Cancer Hospital

    Recurrent or metastatic solid cancer harboring a FGFR1,2 ,3 fusion/rearrangement or activating mutation, outside of the approved indications for any selective FGFR inhibitor in France

    phase 2 small molecule active

    1 trial

  18. Pemazyre 4.5 mg tablets, INCAGN02385, INCAGN02390, Retifanlimab (INCMGA00012)

    Incyte

    Endometrial cancer, Endometrial cancer

    phase 2 small molecule active

    1 trial

  19. Pembrolizumab

    United Therapeutics Europe Ltd

    Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  20. Pembrolizumab

    Genmab A/S

    Advanced Endometrial Cancer

    phase 2 mab terminated

    1 trial

  21. Pembrolizumab

    Incyte

    Lung Cancer

    phase 2 small molecule completed

    2 trials

  22. Pembrolizumab

    Syndax Pharmaceuticals

    Bladder Cancer

    phase 2 small molecule active

    1 trial

  23. Pembrolizumab

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 small molecule active

    1 trial

  24. Pembrolizumab

    United Therapeutics Europe Ltd

    Castration-resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources